Heat-stable carbetocin non-inferior for preventing blood loss of ≥500 ml, use of other uterotonic agents
THURSDAY, July 5, 2018 (HealthDay News) — For women after vaginal birth, heat-stable carbetocin is non-inferior to oxytocin for prevention of blood loss of at least 500 ml or use of additional uterotonic agents, according to a study published online June 27 in the New England Journal of Medicine.
Mariana Widmer, from the World Health Organization in Geneva, and colleagues enrolled women across 23 sites in 10 countries in a non-inferiority trial comparing intramuscular injections of heat-stable carbetocin with oxytocin administered immediately after vaginal birth. A total of 29,645 women were randomized.
“Heat-stable carbetocin was non-inferior to oxytocin for the prevention of blood loss of at least 500 ml or the use of additional uterotonic agents,” the authors write.
The study was funded by Merck Sharpe & Dohme.
Copyright © 2018 HealthDay. All rights reserved.